Recombinant PDCD1 (Pembrolizumab Biosimilar) antibody
The Mammalian Cells Monoclonal anti-PDCD1 (Pembrolizumab Biosimilar) antibody is suitable to detect PDCD1 (Pembrolizumab Biosimilar) in samples from Human. It has been validated for ELISA.
Catalog No. ABIN7487773
$336.06
Plus shipping costs $50.00
Shipping to:
United States
Delivery in 7 to 10 Business Days
Quick Overview for Recombinant PDCD1 (Pembrolizumab Biosimilar) antibody (ABIN7487773)
Target
PDCD1 (Pembrolizumab Biosimilar)
Antibody Type
Recombinant Antibody
Reactivity
Human
Host
Mammalian Cells
Clonality
Monoclonal
Conjugate
This PDCD1 (Pembrolizumab Biosimilar) antibody is un-conjugated
Application
ELISA
Grade
Research Grade
-
-
Expression System
- Mammalian cells
-
Purpose
- Pembrolizumab Biosimilar - Anti-PD1 mAb
-
Characteristics
- Antibody Type: IgG4
-
Purification
- Recombinant antibody expressed in mammalien cells and purified.
-
Isotype
- IgG4
-
-
anti-PDCD1 (Pembrolizumab Biosimilar) antibody
Research Grade Reactivity: Human FACS, ELISA Host: Humanized Monoclonal unconjugated Recombinant Antibody
-
-
Restrictions
- For Research Use only
-
-
-
Buffer
- PBS pH 7.5
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- 4°C for short term, -20°C for long term
-
-
- PDCD1 (Pembrolizumab Biosimilar)
-
Target Type
- Biosimilar
-
Background
-
Pembrolizumab
Pembrolizumab is a humanized (from mouse) monoclonal antibody that binds to, and blocks PD-1 located on lymphocytes. It is an anticancer medication used in the treatment of melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, urothelial cancer (cancer of the bladder and urinary tract) and renal cell carcinoma (kidney cancer).
Target
-
You are here:
